Agios Pharmaceuticals, Inc. (AGIO)
NasdaqGS
Price as at 2 Oct 2026, 01:29 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Agios Pharmaceuticals, Inc. trades at $32.48. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Super investor ownership
9 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Farallon Capital, FARALLON CAPITAL MANAGEMENT, L.L.C.$219.59M · 1.0% of book
- D. E. Shaw, D. E. Shaw & Co., Inc.$115.30M · 0.1% of book
- Arrowstreet Capital, ARROWSTREET CAPITAL, LIMITED PARTNERSHIP$30.08M · 0.0% of book
- Ken Griffin, CITADEL ADVISORS LLC$27.19M · 0.0% of book
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$25.40M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Politician trades in AGIO
Trades in AGIO disclosed by members of Congress and executive-branch officials, latest first:
- Gilbert Cisneros · HouseBuy · $1,001 - $15,000 · traded 20 Aug 2026 · disclosed 10 Sept 2026
- Gilbert Cisneros · HouseBuy · $1,001 - $15,000 · traded 3 Mar 2026 · disclosed 7 Apr 2026
- Gilbert Cisneros · HouseBuy · $1,001 - $15,000 · traded 11 Dec 2025 · disclosed 12 Jan 2026
- Gilbert Cisneros · HouseBuy · $1,001 - $15,000 · traded 17 Apr 2025 · disclosed 6 May 2025
- Gilbert Cisneros · HouseBuy · $1,001 - $15,000 · traded 29 Jan 2025 · disclosed 11 Feb 2025
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
Common questions
Which funds own AGIO?
9 of the institutions we track reported a position in AGIO in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its AGIO data?
Fundamentals for AGIO come from company filings and exchange data, as listed on NasdaqGS; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 2 Oct 2026, 01:29 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for AGIO, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.